Molecular hydrogen for outpatients with Covid-19 (Hydro-Covid): a phase 3, randomised, triple-blinded, adaptive, placebo-controlled, multicentre trial

Author:

Gaboreau YoannORCID,Milovančev Aleksandra,Rolland Carole,Eychenne Claire,Alcaraz Jean-Pierre,Ihl Cordelia,Mazet Roseline,Boucher François,Vermorel Celine,Ostojic Sergej M.ORCID,Borel Jean Christian,Cinquin PhilippeORCID,Bosson Jean-Luc,

Abstract

AbstractBackgroundDue to its antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties, molecular hydrogen (H2) is potentially a novel therapeutic gas for acute coronavirus disease 2019 (COVID-19) patients.AimTo determine the efficacy and safety profile of hydrogen rich water (HRW) to reduce the risk of progression of COVID-19.Design and settingsWe conducted a phase 3, triple-blind, randomized, placebo-controlled trial to evaluate treatment with HRW started within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19 and at least one risk factor for severe COVID-19 illness.MethodParticipants were randomly assigned to receive HRW or placebo twice daily for 21 days. The composite primary endpoint was the incidence of clinical worsening (dyspnea, fatigue) associated with a need for oxygen therapy, hospitalization or death at day-14; the incidence of adverse events was the primary safety end point.ResultsA total of 675 participants were followed up until day-30. 337 in the HRW group and 338 in the placebo group. Baseline characteristics were similar in the two groups. HRW was not superior to placebo in preventing clinical worsening at day-14: in H2group, 46.1% met a clinical deterioration, 43.5% in the placebo group, Hazard Ratio 1.09, 90% confidence interval [0.90-1.31]. One death was reported in the H2group and 2 in the placebo group at day-30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants respectively.ConclusionTwice-daily ingestion of HRW from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening.How this fits inOnly a few molecules specially developed against SARS-CoV-2 can limit impact of COVID-19 (vaccines, monoclonal antibodies or antiviral drugs)Using their multiple properties, H2 may play a key role in preventing the severe and post-acute forms of COVID-19Taking twice daily Hydrogen Rich Water (HRW) was not efficacious to prevent severe COVID-19 in at risk COVID-19 patients.HRW confirmed a very safe profil

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3